Truist Financial Corp Has $19.65 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Truist Financial Corp lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 972,915 shares of the company’s stock after selling 38,775 shares during the period. Truist Financial Corp’s holdings in Teva Pharmaceutical Industries were worth $19,653,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $41,000. Cromwell Holdings LLC raised its stake in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. MAI Capital Management lifted its position in Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth $65,000. Finally, CWM LLC increased its holdings in Teva Pharmaceutical Industries by 18.1% in the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after buying an additional 767 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 fundamentals beat expectations — Teva reported stronger-than-expected results (reported EPS and revenue outperformed consensus), revenue grew year-over-year driven by a Sanofi milestone and Austedo growth, and management set FY‑2026 EPS guidance of roughly 2.57–2.77, supporting a higher valuation. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Barclays raised its price target to $38 and set an “overweight” rating, signaling upside from current levels and lending third‑party validation to the stock’s outlook. Barclays raises TEVA price target to $38
• Positive Sentiment: Truist increased its price target to $38 with a “buy” rating, reinforcing bullish analyst sentiment following the quarter. Truist raises TEVA price target to $38
• Positive Sentiment: Scotiabank lifted its target to $40 and moved to “sector outperform,” the highest target among recent broker notes, which may attract more investor interest. Scotiabank raises TEVA price target to $40

Analysts Set New Price Targets

A number of research analysts have commented on TEVA shares. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. Barclays increased their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Friday. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Scotiabank upped their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday. Finally, Jefferies Financial Group increased their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider directly owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. The trade was a 28.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 622,060 shares of company stock worth $17,076,965. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 3.1%

Shares of TEVA opened at $34.08 on Friday. The business’s fifty day moving average price is $30.49 and its two-hundred day moving average price is $23.15. The firm has a market capitalization of $39.09 billion, a price-to-earnings ratio of 28.40, a PEG ratio of 1.88 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $34.11. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.